statistiche ricercatore

Continente	#
NA - Nord America	379
AS - Asia	346
EU - Europa	287
SA - Sud America	51
AF - Africa	11
Continente sconosciuto - Info sul continente non disponibili	2
Totale	1.076

Nazione	#
US - Stati Uniti d'America	372
SG - Singapore	169
IT - Italia	74
CN - Cina	53
IE - Irlanda	42
BR - Brasile	41
HK - Hong Kong	38
RU - Federazione Russa	32
DE - Germania	31
VN - Vietnam	31
FI - Finlandia	22
FR - Francia	19
NL - Olanda	19
KR - Corea	17
GB - Regno Unito	10
IN - India	10
BD - Bangladesh	8
SE - Svezia	7
AR - Argentina	6
AT - Austria	6
PL - Polonia	6
UA - Ucraina	6
IQ - Iraq	4
MA - Marocco	4
TR - Turchia	4
CA - Canada	3
JP - Giappone	3
CO - Colombia	2
CR - Costa Rica	2
ES - Italia	2
LT - Lituania	2
MX - Messico	2
PT - Portogallo	2
XK - ???statistics.table.value.countryCode.XK???	2
AL - Albania	1
BE - Belgio	1
BG - Bulgaria	1
BY - Bielorussia	1
CH - Svizzera	1
CZ - Repubblica Ceca	1
DZ - Algeria	1
EC - Ecuador	1
ET - Etiopia	1
GE - Georgia	1
ID - Indonesia	1
IL - Israele	1
KE - Kenya	1
KG - Kirghizistan	1
LB - Libano	1
LY - Libia	1
ME - Montenegro	1
MN - Mongolia	1
PE - Perù	1
PH - Filippine	1
PK - Pakistan	1
TL - Timor Orientale	1
TN - Tunisia	1
TZ - Tanzania	1
ZA - Sudafrica	1
Totale	1.076

Nome	#
Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma	139
Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial	121
Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia.	108
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity	108
Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients	107
THE BRAF-MEK-ERK PATHWAY IN HAIRY CELL LEUKEMIA: A COMPREHENSIVE DISSECTION IN PRIMARY LEUKEMIC CELLS OF ITS BIOLOGICAL AND THERAPEUTIC RELEVANCE	105
Biological and therapeutic relevance of the BRAF-MEK-ERK pathway in hairy cell leukemia	98
The gene mutation landscape of acute myeloid leukemia cell lines and its exemplar use to study the BCOR tumor suppressor	94
Venetoclax in Relapsed or Refractory Hairy-Cell Leukemia	58
An unusual form of BRAF‐V600E mutated hairy cell neoplasm with clinical resistance to BRAF inhibition: Challenging precision medicine	52
Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall	51
Targetable Mutations in BRAF V600E–Negative Hairy-Cell Leukemia	31
Classic Hairy Cell Leukemia With MAP2K1 Mutation: Diagnosis and Targeted Therapy	26
Independent Origin of Hairy Cell Leukemia (HCL) From Co-Occurring Clonal Hematopoiesis (CH)	23
Totale	1.121

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	6	0	0	0	0	0	0	0	0	0	5	1	0
2021/2022	75	4	18	0	2	1	0	0	20	3	5	14	8
2022/2023	145	7	24	2	17	16	12	0	3	56	5	1	2
2023/2024	87	5	4	9	0	0	0	21	0	6	5	21	16
2024/2025	233	13	17	11	17	22	15	14	24	32	5	34	29
2025/2026	486	42	23	21	42	120	56	70	21	55	36	0	0
Totale													1.121

IRIS - Res&Arch Institutional Research Information System - Research & Archive